Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1081-1100 of 1,694 trials

Retinitis Pigmentosa: Stem Cell Eye Treatment

We are testing a new stem cell-based treatment for people with retinitis pigmentosa to see if it is safe and tolerable. The study also aims to evaluate its potential to improve vision.

Retinitis Pigmentosa1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Stroke Prevention: Low Dose Colchicine Study

We are investigating whether low dose colchicine can help prevent future strokes and other major vascular events in patients with a history of stroke due to atherosclerosis.

Cardiovascular Diseases>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Obesity: PF-07976016 Medication Study

We are testing a new medication called PF-07976016 to see if it helps adults with obesity lose weight more effectively than a placebo. The study also looks at the safety of this medication for those already taking liraglutide.

ObesityOverweight6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteDiabetologyEndocrinology

Idiopathic Inflammatory Myopathies: Upadacitinib Study

We are testing whether Upadacitinib can help patients with idiopathic inflammatory myopathies maintain stable disease after stopping IVIG treatment. The study compares its effects to a placebo over 16 weeks.

PolymyositisDermatomyositisAntisynthetase Syndrome3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesDermatologyRheumatology

Heart Attack Recovery: Bempedoic Acid Study

We are investigating whether adding bempedoic acid to standard cholesterol medications helps heart attack patients reach their cholesterol goals. This study aims to improve treatment for those not meeting guidelines with current therapies.

Heart Attack1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Atrial Fibrillation: Dapagliflozin Treatment Study

We are investigating if dapagliflozin can help prevent the return of atrial fibrillation after cardioversion compared to usual care. This study aims to see how well it works in prolonging the time before atrial fibrillation recurs.

Atrial Fibrillation≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Triple-Negative Breast Cancer: Ceralasertib with Durvalumab and Nab-Paclitaxel

We are studying a new treatment approach for patients with advanced triple-negative breast cancer who have relapsed after prior therapies. This trial aims to see if combining ceralasertib with other medications can improve their response to treatment.

Advanced Triple Negative Breast Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Metastatic Colorectal Cancer: Trifluridine/Tipiracil with Panitumumab vs. Bevacizumab

We are studying two treatment combinations to find out which one works better for people with metastatic colorectal cancer. The trial also looks at safety and how treatments affect patients' quality of life.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Angiosarcoma and Undifferentiated Pleomorphic Sarcoma: Propranolol and Pembrolizumab Study

We are studying the effects of a new treatment combining propranolol and pembrolizumab for patients with advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma. The goal is to see if this combination improves survival and quality of life.

Advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

IDH1/IDH2-Mutant Glioma: Vorasidenib with Temozolomide

We are studying the safety and effectiveness of a new drug, vorasidenib, combined with temozolomide for patients with IDH1- or IDH2-mutant gliomas. This research aims to see if this combination can improve treatment outcomes.

IDH1-mutant GliomaIDH2-mutant Glioma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Sickle Cell Disease: Hydroxycarbamide Tablets for Children

We are studying the effects of a twice-daily dose of Hydroxycarbamide in children with sickle cell disease. This trial aims to evaluate its safety, effectiveness, and how well children tolerate the treatment.

Sickle Cell Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Cystic Fibrosis: VX-121/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for children with cystic fibrosis to evaluate its safety and how well it works. This trial focuses on kids aged 1 to 11 years.

Cystic Fibrosis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Karonudib for Blood Cancers: Phase 1 Study

We are evaluating the safety and tolerability of Karonudib in patients with advanced blood cancers like Acute Myeloid Leukemia and Multiple Myeloma. This study aims to find the best dose and understand how well it works with other cancer treatments.

Blood Cancers>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Kidney Transplant: Eight Treg Immunotherapy

We are testing a new treatment using expanded regulatory T cells for living donor kidney transplant recipients. The goal is to see if this approach is safe and may reduce the need for traditional immunosuppressive medications.

Chronic Kidney FailureSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Rare Cancers: Targeted Drug Study

We are exploring how well existing targeted cancer drugs work for patients with rare and hard-to-treat cancers. The study will also look at any serious side effects from these treatments.

Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Knee Surgery Pain Relief: Nefopam Study

We are investigating whether an oral medication called nefopam can reduce morphine use after total knee replacement surgery. This study aims to improve pain management for adults recovering from this procedure.

Postoperative Pain After Knee Surgery>2 yearsSafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineOrthopedics and Traumatology

Acute Myocarditis: Ibuprofen vs. Standard Pain Relief

We are studying whether ibuprofen can better improve heart health compared to regular pain relief in patients with acute myocarditis. This trial focuses on how these treatments affect heart imaging results after six months.

Acute Myocarditis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Endurance Performance: Pseudoephedrine Study

We are investigating how a full dose of pseudoephedrine affects cycling performance in trained athletes after a tough race simulation. The study also looks at the right dosage and the body's response to it.

Healthy Volunteers6-12 monthsMonitoring phase (IV)Investigational MedicinesInternal MedicinePediatrics

Kidney Transplant Rejection: Everolimus Study

We are studying whether everolimus can help kidney transplant patients with a specific type of rejection maintain kidney function and reduce damage. This trial looks at its effects over six months.

Kidney Failure6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesNephrology

Giant Cell Arteritis and Polymyalgia Rheumatica: Hydrocortisone Study

We are investigating whether hydrocortisone can help patients with GCA and PMR who report symptoms of adrenal insufficiency after stopping glucocorticoids. This study aims to provide better treatment options for these patients.

Tertiary Adrenal Insufficiency>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology